Tirzepatide for Recurrent Weight Gain after Bariatric Procedures: Real-World Evidence of Efficacy and Safety - Quiz - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

Efficacy and Safety of Tirzepatide in Managing Recurrent Weight Gain Following Bariatric Surgery: Insights from Real-World Data

  • By

  • Federica Vinciguerra

  • Carla Di Stefano

  • Fabio Guccione

  • Claudia Degano

  • Stefania Nigro

  • Roberto Baratta

  • Luigi Piazza

  • Giuseppe Navarra

  • Lucia Frittitta

  • June 5, 2026

Share

Original Source(s)

Tirzepatide for Recurrent Weight Gain after Bariatric Procedures: Real-World Evidence of Efficacy and Safety

  • by Federica Vinciguerra, Carla Di Stefano, Fabio Guccione, Claudia Degano, Stefania Nigro, Roberto Baratta, Luigi Piazza, Giuseppe Navarra, Lucia Frittitta

  • June 5, 2026

Related Content

10 CMS and FDA Actions Affecting Care in 2026

From Medicare payment updates to drug approvals and device access, these federal actions may affect reimbursement, prescribing, patient access, and clinical workflows.

HHS Proposes Mandatory GRAS Notices

Manufacturers would be required to notify the FDA of GRAS determinations under a proposed rule, while HHS and USDA also submitted the first proposed federal definition of ultra-processed foods for final review.

CGM Linked to More Time in Range

In a randomized crossover trial of insulin-treated patients receiving hemodialysis, real-time continuous glucose monitoring did not improve the primary hypoglycemia outcome but increased time in range and reduced time above range vs capillary testing.